- Home
- TR vs DYN Comparison
TR vs DYN Comparison
Compare TR & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TR | DYN |
|---|---|---|
| Founded | 1896 | 1984 |
| Country | United States | United States |
| Employees | 2100 | N/A |
| Industry | Specialty Foods | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.1B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | TR | DYN |
|---|---|---|
| Price | $40.71 | $17.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $37.00 |
| AVG Volume (30 Days) | 96.0K | ★ 1.4M |
| Earning Date | 04-23-2026 | 05-04-2026 |
| Dividend Yield | ★ 0.85% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $32.36 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $32.63 | $8.25 |
| 52 Week High | $45.06 | $25.00 |
Technical Indicators
Market Signals| Indicator | TR | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 40.44 | 43.02 |
| Support Level | $40.15 | $16.57 |
| Resistance Level | $43.38 | $19.52 |
| Average True Range (ATR) | 1.30 | 0.89 |
| MACD | -0.22 | -0.05 |
| Stochastic Oscillator | 31.23 | 15.27 |
Price Performance
Historical ComparisonAbout TR Tootsie Roll Industries Inc.
Tootsie Roll Industries Inc manufactures and sells confectionery products. Notable varieties include Tootsie Roll and Tootsie Pops, Charms, Blow-Pops, Dots, Junior Mints, Sugar Daddy and Sugar Babies, Andes, Dubble Bubble, Razzles among others. The company sells its products to wholesale distributors and directly to retail stores. Geographically, it generates a majority of its revenue from the United States and rest from Canada, Mexico and other regions.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.